Reference
1. Crompton J A , North D S , Minjung Y , et al. Outcomes with
daptomycin in the treatment of Staphylococcus aureus infections with a
range of vancomycin MICs[J]. Journal of Antimicrobial
Chemotherapy,2010,65(8):1784.
2. A.M. Casapao, T.P. Lodise, S.L. Davis, et al., Association between
Vancomycin Day 1 Exposure Profile and Outcomes among Patients with
Methicillin-Resistant Staphylococcus aureus Infective Endocarditis,
Antimicrobial Agents and Chemotherapy. 2015, 59 (6): 2978–2985.
3. J.S. Davis, for the Australasian Society for Infectious Diseases
Clinical Research N, A. Sud, et al., Combination of Vancomycin and
β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus
Bacteremia: A Pilot Multicenter Randomized Controlled Trial, Clinical
Infectious Diseases. 2016. 62 (2) :173–180.
4. A. Petrarca, C. Burant, U. Stiefel, et al., Outcomes of Bloodstream
Infections (BSI) Caused by Coagulase-Negative Staphylococcus (CoNS) With
Elevated Minimum Inhibitory Concentration (MIC) to Vancomycin at a
Tertiary Care Veterans Affairs (VA) Medical Center, Open Forum
Infectious Diseases. 2016.
5. McCormick M H, McGuire J M, Pittenger G E,et al.Vancomycin, a new
antibiotic. I. Chemical and biologic properties[J]. Antibiot
Annu,1955,3: 606-611.
6. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of
vancomycin for serious methicillin-resistant Staphylococcus aureus
infections: A revised consensus guideline and review[J]. American
journal of health-system pharmacy. 2020,77(11)835-864.
7. Zhichao H, Junyan W, Kaifeng Q.
Guidelines for clinical pharmacists
for individualized administration of vancomycin [J]. Daily Medical
Journal. 2015(2);78-82.
8. Jeffres M N, Isakow W , Doherty J A , et al. A retrospective analysis
of possible renal toxicity associated with vancomycin in patients with
health care-associated methicillin-resistant Staphylococcus aureus
pneumonia[J]. Clinical Therapeutics, 2007,29(6): 0-1115.
9. Carreno JJ, Jaworski A, Kenney RM, Davis SL. Comparative incidence of
nephrotoxicity by age group among adult patients receiving vancomycin.
Infect DisTher,2013,2(2): 201-208.
10. Bruniera F R, Ferreira F M, Saviolli L R M, et al. The use of
vancomycin with its therapeutic and adverse effects: a review[J].
2015,19(4): 694-700.
11.Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated
nephrotoxicity: a critical appraisal of risk with high-dose
therapy[J]. int j antimicrob agents, 2011, 37(2): 95-101.
12. Paediatric Formulary Committee. British National Formulary for
Children 2011-2012. London, UK: Pharmaceutical Press; 2012.
13. Zhang M , Huang X L , Yahui W , et al. A rapid and simple UPLC
method for serum vancomycin determination in pediatric patients
undergoing continuous infusion or intermittent infusion of
vancomycin[J]. Journal of Pharmaceutical and Biomedical Analysis,
2019, 174: 214-219.
14. National Health and Family Planning Commission of China. the Guiding
Principles of Clinical Use of Antibiotics. Official website of the
National Health and Family Planning Commission ,China. 2015.
15. Forouzesh A, Moise PA, Sakoulas G. Vancomycin Ototoxicity: a
Reevaluation in an Era of Increasing Doses[J]. Antimicrobial Agents
& Chemotherapy, 53(2): 483-486.
16. H. Padari, K. Oselin, T. Tasa, et al., Coagulase negative
staphylococcal sepsis in neonates: do we need to adapt vancomycin dose
or target?. BMC Pediatrics. 16(1) (2016) 206
17. A. Hahn, R.W. Frenck Jr., M. Allen-Staat, et al., Evaluation of
Target Attainment of Vancomycin Area Under the Curve in Children With
Methicillin-Resistant Staphylococcus Aureus Bacteremia, Therapeutic drug
monitoring. 37 (5)(2015) 619-625.
18. Tafelski S , Nachtigall I , Troeger U, et al. Observational clinical
study on the effects of different dosing regimens on vancomycin target
levels in critically ill patients: Continuous versus intermittent
application[J]. Journal of Infection and Public Health, 2015,
8(4):355-363.
19. Adriana C M , Evelina T , Elisabetta G , et al. Continuous versus
intermittent infusion of vancomycin for the treatment of Gram-positive
infections: systematic review and meta-analysis[J]. Journal of
Antimicrobial Chemotherapy 2012;67(1):17–24.
20. Zhao W, Zhang D, Fakhoury M, et a1. Population pharmacokinetics and
dosing optimization of vancomycin in children with malignant
hematological disease[J]. Antimicrob Agents Chemother, 2014,58(6):
3191-3199.
21. Cardoso Bourguignon da Silva, Dáfne, Toribio Finoti Seixas, Gláucia,
Orlei RDA, et al. Vancomycin serum concentrations in pediatric
oncologic/ hematologic intensive care patients[J]. Brazilian Journal
of Infectious Diseases, 2012,16(4):361-365.
22. Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner
SH, et al. Telavancin and vancomycin pharmacodynamics with
Staphylococcus au-reus in an in vitro dynamic model. J Antimicrob
Chemother 2008; 62 :10651069.
23. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.
Pharmacodynamics of vancomycin and other antimicrobials in patients with
Staphylococcus aureus lower respiratory tract infections. Clin
Pharmacokinet 2004; 43: 925–42.
24. A. Hahn, R.W. Frenck Jr., M. Allen-Staat, et al, Evaluation of
Target Attainment of Vancomycin Area Under the Curve in Children With
Methicillin-Resistant Staphylococcus Aureus Bacteremia, Therapeutic drug
monitoring. 37 (5)(2015) 619–625.
25. T raverso F , Peluffo M , Louge M, et al. Impact of methicillin
resistance on mortality and surveillance of vancomycin susceptibility in
bacteremias caused by Staphylococcus aureus[J]. Revista Argentina de
microbiología, 2010, 42(4):274-278.
26. Kassim A , Omuse G , Premji Z , et al. Comparison of Clinical
Laboratory Standards Institute and European Committee on Antimicrobial
Susceptibility Testing guidelines for the interpretation of antibiotic
susceptibility at a University teaching hospital in Nairobi, Kenya: a
cross-sectional study[J]. Annals of Clinical Microbiology &
Antimicrobials, 2016, 15(1):21.
27. He N, Su S, Ye ZK, et al. Evidence-based guideline for therapeutic
drug monitoring of vancomycin: 2020 update by the Division of
Therapeutic Drug Monitoring, Chinese Pharmacological Society[J].
Clin Infect Dis, 2020.71: S363-S371.
28 Verrall AJ, Ryan L, Tam VH, et al. Efficacy of continuous infusion of
vancomycin for the outpatient treatment of methicillin-resistant
Staphylococcus aureus infections[J]. J Antimicrob Chemother, 2012,
(12): 2970-2973.
29. Giulia DA, Adriana CM, Chiara DW, et al. Infection control and
prevention measures to reduce the spread of vancomycin-resistant
enterococci in hospitalized patients: a systematic review and
meta-analysis[J]. J Antimicrob Chemother, 2014, (5): 1185-92.
30. Rhodes N J , Prozialeck W C , Lodise T P , et al. Evaluation of
Vancomycin Exposures Associated with Elevations in Novel Urinary
Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats[J].
Antimicrobial Agents & Chemotherapy, 2016;60(10):5742–5751.
31. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin
doses (at least four grams per day) are associated with an increased
incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008
Apr;52(4):1330-6.